<DOC>
	<DOCNO>NCT00712855</DOCNO>
	<brief_summary>The purpose study evaluate safety tolerability escalate dos mapatumumab combination sorafenib subject advance Hepatocellular Carcinoma positive hepatitis B surface antigen hepatitis C antibody .</brief_summary>
	<brief_title>A Study Mapatumumab Combination With Sorafenib Subjects With Advanced Hepatocellular Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Moderate liver disease Test positive hepatitis B surface antigen hepatitis C antibody Locally advance unresectable/untransplantable metastatic hepatocellular carcinoma Age 18 year old Received investigational ( yet approve regulatory authority ) noninvestigational agent treat hepatocellular carcinoma . Received radiation therapy within 4 week randomization Major surgery within 4 week randomization Minor surgery within 2 week randomization Systemic steroid within 1 week randomization Hepatic encephalopathy , per investigator 's evaluation History clinically significant gastrointestinal bleeding require procedural intervention within 4 week enrollment History infection require hospitalization antibiotic within 2 week randomization Known brain spinal cord metastases History cancer within 5 year enrollment Pregnant breastfeeding woman Known HIV infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>Liver Cancer</keyword>
</DOC>